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Abstract 
 
Psoriasis is a chronic inflammatory disease that affects 2-3% of the worldwide 
population.  It is characterized by an epidermal hyperproliferation and an inflammatory cell 
infiltrate into the epidermis and dermis that results in the development of psoriatic lesions. 
Presently, the drugs used for treatment are generally immunosuppressive agents that either 
suppress the activation of immune response cells or inhibit cytokine/chemokine molecules that 
promote the inflammatory microenvironments characteristic of psoriasis pathophysiology.  It has 
been reported that the target region of the psoriasis susceptibility locus (PSORS1) harbors a 
fragment of a human endogenous retrovirus K (HERV-K), which encodes for a deoxyuridine 
triphosphate nucleotidohydrolase (dUTPase).  Our hypothesis is that the HERV-K dUTPase 
protein triggers a Th1, Th17 cytokine response by activating NF-κB through toll-like receptor 2 
(TLR2).  The goal of my study was to identify the region of the HERV-K dUTPase responsible 
for activating TLR2.  To accomplish this I constructed three specific deletion constructs (∆60-
171; ∆90-171; and ∆110-171) of the consensus HERV-K dUTPase sequence via PCR 
amplification and cloned these DNA fragments into the pTrcHis vector for expression and 
subsequent purification of the recombinant proteins.  The recombinant proteins were purified 
using cobalt affinity chromatography.  The purified recombinant proteins will be used to 
determine structural characteristics of the recombinant protein and to determine whether these 
mutant proteins activate a NF-κB recorder gene in human embryonic kidney (HEK-293) cells 
expressing TLR2.  We believe that successful completion of our studies will enable our research 
group to pursue development of a vaccine to generate antibodies that specifically target our 
identified region and thus provide a novel alternative treatment option for psoriasis patients. 
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Introduction 
 
 Psoriasis is an inheritable chronic inflammatory disease of the skin affecting 2-3% of the 
world's population.  It is characterized by an epidermal hyperproliferation and an inflammatory 
cell infiltrate into the epidermis and dermis that typically results in the development of psoriatic 
lesions.  Previous epidemiological and genetic studies have indicated that the establishment of 
the disease can be attributed to a variety of risk genes, environmental factors, excessive stress, 
trauma, and a variety of innate and adaptive immune cell interactions which are responsible for 
the production and secretion of various cytokines and chemokines commonly attributed to 
psoriasis symptomology (Lowes et al., 2007; Nickoloff 2007; Nickoloff et al., 2007; Nestle et al., 
2009).  
 The psoriasis susceptibility locus 1 (PSOR1), located in the major histocompatibility 
complex on chromosome 6p21, has been identified as the strongest genetic determinant of 
psoriasis, accounting for 35-50% of the heritability of the disease.  Recent haplotype sharing 
analysis has revealed that the PSOR1 locus contains fragments of the human endogenous 
retrovirus K (HERV) genome, specifically segments of the C-terminal gag gene and the N-
terminal pro gene, which harbors the region encoding the deoxyuridine triphosphate 
nucleotidohydrolase (dUTPase) (Foerster et al., 2005).  
 HERVs are known to constitute approximately 7-8% of the human genome and are the 
result of ancient exogenous retroviruses infecting human germ-cell lines millions of years ago 
(Lower et al., 1995).  It is thought that these endogenous proviruses may have conferred 
protection to their hosts from superinfection by pathogenic exogenous counterparts and thus 
provides explanation for their maintenance within the human genome (Lower et al., 1995). 
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Endogenous retrovirus genomes have undergone a variety of mutational events since their 
incorporation into the human genome and have thus lost their ability to retrotranspose, replicate, 
and infect additional cells.  As such, HERV genomes no longer encode for completely intact 
virions, but rather a variety of proteins that have generally undergone mutational development 
over time.  The fact that these HERV open reading frames are still intact indicates potential 
protein functionality within the host (Lower et al., 1995).  However, there are several reports that 
have linked both human endogenous and exogenous retroviruses to the development of 
autoimmune disorders including psoriasis (Bannert and Kurth, 2004; Colmegna and Garry, 2006; 
Guilhou and Moles, 2008).  HERV-K is generally recognized as the most biologically active 
endogenous retrovirus and until now has been largely associated with its role in development of 
seminoma, melanoma, and insulin-dependent diabetes mellitus (Voisset et al., 2008).  The recent 
link between the PSOR1 HERV-K encoded dUTPase and psoriasis symptomology is further 
supported by detection of HERV-K encoded dUTPase RNA in peripheral blood mononuclear 
cells (PBMCs) of psoriasis patients using RT-PCR analysis (Foerster et al., 2005). 
 HERV-K is classified as an endogenous beta retrovirus. As a result of a slippery 
sequence (poly U region followed by a hairpin loop) in the beta retrovirus genome, ribosomal 
frameshifting occurs which enables the ribosome to transcribe both the gag and pro genes 
consecutively, leading to formation of a Gag-Pro polyprotein. Cleavage of the polyprotein results 
in the formation of a NC-dUTPase fusion protein, which is not subject to the proteolytic activity 
separating the nucleocapsid from the dUTPase common to all other retroviruses (Nemeth-
Pongracz et al., 2006).  
 dUTPase proteins, metalloenzymes found in all living organisms, hydrolytically cleave 
dUTP into dUMP and pyrophosphate, thus preventing DNA polymerase from incorporating 
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dUTP into DNA during DNA replication (McGeoch, 1990; Mayer and Meese, 2003). 
Homotrimeric (Figure 1) and monomeric dUTPases contain five highly conserved domains that 
allow for enzymatic activity.  A previous study on the Mason-Pfizer Monkey Virus, a beta 
exogenous retrovirus, has indicated that both domains II and V are essential for enzymatic 
activity in addition to revealing the inherent flexibility of domain V (Nemeth-Pongracz et al., 
2006).  Enzyme kinetic studies have revealed that for beta exogenous retroviruses, the NC-
dUTPase fusion protein is fully functional, as the dUTPase is not sterically hindered by the 
presence of the fused nucleocapsid protein (Nemeth-Pongracz et al., 2006).  Although the 
HERV-K dUTPase contains the first four conserved domains, its fifth domain is the least 
conserved (Figure 2).  The HERV-K dUTPase however has been shown to posses zero 
enzymatic activity (Harris et al., 2007; Ariza and William, 2011).  
 While all human herpes viruses form monomeric dUTPases that likely evolved from 
human dUTPases via tandem repeat duplication, the human, beta (endogenous and exogenous) 
retroviral, and most bacterial dUTPases form homotrimeric quaternary structures.  The three 
active sites of homotrimeric dUTPases are formed via the interaction of domains I, II, and IV 
from one monomer with domain III from an adjacent monomer.  Arm swapping occurs between 
each monomer's characteristically flexible domain V, which acts as a movable arm presenting 
dUTP to the active site (Nemeth-Pongracz et al., 2006) (Figure 1).  Conversely, a monomeric 
dUTPase has rearranged the five conserved domains from a numerically consecutive order as 
that found in a homotrimeric dUTPase to an order consisting of domain III, I, II, IV, and V.  
With this rearrangement, the N-terminal domain III folds back onto domains I, II, and IV to form 
the active site, while the C-terminal domain V again works as a flexible arm bringing the dUTP 
substrate to the active site. 
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Figure 1. 
 
 
 The first evidence of a dUTPase possessing immunomodulatory activity was 
demonstrated by Drs. Ariza and Williams' group (Glaser et al., 2006, Ariza et al., 2009) using the 
Epstein-Barr Virus (EBV) encoded dUTPase.  EBV is a gamma herpes virus and thus its 
dUTPase has a monomeric quaternary structure.  PBMCs, induced to proliferate via anti-CD3-
mAb, were treated with purified EBV-encoded dUTPase, which resulted in the arrest of T-cell 
replication, while unstimulated PBMCs treated with purified EBV-encoded dUTPase had 
upregulated proinflammatory cytokine expression including TNF-α, IL-1β, and IL-8 (Glaser et 
al., 2006).  Furthermore, the EBV-encoded dUTPase was demonstrated to induce comparable 
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immune dysregulation in human monocyte-derived macrophages (hMDM)-CD14+ via activation 
of the NF-κB transcription factor (Ariza et al., 2009).  A subsequent study used a luciferase 
reporter assay with a HEK-293 stable cell lines expressing TLR2 to demonstrate that purified 
EBV-encoded dUTPase activated NF-κB through TLR2 and that this signaling cascade was 
dependent on the MyD88 adaptor signaling molecule (Ariza et al., 2009). 
 The discovery of EBV-encoded dUTPase immunomodulatory activity and identification 
of a HERV-K encoded dUTPase within the PSOR1 locus prompted our research group to 
develop studies to determine if the HERV-K encoded dUTPase possesses comparable 
immunomodulatory functionality in the context of psoriasis.  Because psoriasis is characterized 
by chronic epidermal hyperproliferation and inflammation, it is logical to hypothesize that the 
HERV-K encoded dUTPase could function with a mechanism similar to the EBV-encoded 
dUTPase in initiating the production of proinflammatory cytokines.  Initial studies conducted by 
Drs. Ariza and Williams revealed that the HERV-K dUTPase was able to induce activation of 
NF-κB through TLR2 and that treatment of human primary cells with the HERV-K dUTPase 
resulted in the Th1, Th17 cytokine response associated with the induction of psoriasis 
symptomology (Ariza et al., 2011 In Press Journal of Investigative Dermatology).  Specifically, 
TNF-α, IL-23, IL-17, IL-9, IL12p40, and INF-γ, which are associated with the production of 
psoriatic plaques, and CCL20 and RANTES, which are chemokines involved in leukocyte 
recruitment to the skin, were produced by the human primary cells in these studies (Ariza et al., 
2011 In Press Journal of Investigative Dermatology).  Not only did the wild-type (WT) HERV-K 
encoded dUTPase reveal immunomodulatory activity, but C-terminal deletions from the WT 
dUTPase produced enhanced activation of NF-κB through TLR2.  Specifically, our lab 
developed the mutant 16 HERV-K dUTPase, lacking the C-terminal 30 amino acids (∆ 141-171), 
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which was shown to increase NF-κB activation by 31.5 fold.  This result indicated that the region 
between amino acid 141 and 171 could be important in the regulation of NF-κB activation 
through TLR2.  
Various drugs that are administered either topically or systemically, depending upon the 
severity of the disease, are used to treat patients with psoriasis (Lowes et al., 2007).  These 
agents are generally immune modulators, which suppress the activation of cells involved in the 
immune response and/or inhibit the action of key cytokines reported to contribute to the 
inflammatory reaction that occurs in psoriasis.  While these agents can be effective, they do not 
target the event(s) that trigger the cytokine cascade associated with psoriasis, but rather the 
immune response.  In doing so, these drugs increase the risk of patients developing infections by 
various microorganisms.  Our strategy bypasses these negative side effects by targeting the 
source of psoriasis symptoms, which we believe to be the interaction of the HERV-K dUTPase 
with TLR2.  Based upon our previous studies, our working hypothesis is that mutations in the 
HERV-K dUTPase gene can increase TLR2 interaction and thus contribute to the initiation of 
psoriasis.  The primary goal of my thesis project was to specifically determine the amino acid 
region of the HERV-K dUTPase responsible for activating TLR2.  To achieve this task, I 
constructed three C-terminal deletion constructs from the consensus HERV-K dUTPase 
sequence, which I termed mutant 60 (∆60-171), mutant 90 (∆90-171), and mutant 110 (∆110-
171).  Because both the WT and mutant 16 HERV-K dUTPase form a homotrimer, as previously 
demonstrated by gel filtration assays, it was also important to determine if the C-terminal 
deletions resulted in monomeric proteins and whether or not the structural difference played a 
role in the activation of TLR2.  
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Materials and Methods 
 
Competent Cells 
  An E. coli (BL21(DES)pLysS) colony was selected to start an overnight culture in LB 
media in the absence of antibiotics.  A sample of the overnight culture (1 mL) was transferred to 
a flask containing LB media (100 mL) and incubated at 37°C until an OD600 of 0.5 was 
obtained.  The flask was chilled on ice (20 min) and the cells were harvested via centrifugation 
(4000 rpm, 15 min, 4°C).  The pellet was resuspended in resuspension buffer (85% LB medium, 
10% PEG (MW 8000), 5% DMSO, 50 mM MgCl2), aliquoted, and stored at -70°C. 
 
Generation of Deletion Constructs 
 PCR amplification of Del 60 (∆60-171), Del 90 (∆90-171), and Del 110 (∆110-171) was 
performed on the consensus HERV-K dUTPase sequence using primers found in Figure 3B and 
PCR supermix (Invitrogen).  The following PCR conditions were used: Denaturation at 94°C for 
4 min (1 cycle), followed by 35 cycles of 94°C for 30 sec, 55°C for 30 sec, 72°C for 1 min, and 
one cycle at 72°C for 10 min.  PCR products were analyzed by gel electrophoresis as they were 
run on a 1% agarose gel in TAE buffer and subsequently extracted from the gel using the 
QIAquick (QIAGEN) Gel Extraction Kit according to the manufacturer's instructions. 
 
Cloning 
 The PCR amplified DNA fragments were cloned into pTrcHis plasmids using the 
Invitrogen pTrcHis Topo TA Cloning Kit according to the manufacturer's instructions and were 
used to transform BL21(DES)pLysS competent cells (figure 4).  Briefly, plasmids were added to 
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the BL21(DES)pLysS competent cells and incubated on ice for 30 min.  The cells were heat 
shocked for 2 min at 42°C and immediately transferred to ice.  Room temperature SOC media (1 
mL) was added to each cell mixture and incubated at 37°C for 2 hours while shaking.  The 
transformed cell cultures were diluted four-fold with SOC media and spread (25 µL) onto 
separate petri dishes with LB media (50 µg/mL ampicillin, 0.5% glucose) and incubated 
overnight at 37°C.  Colonies were selected from each transformation reaction and grown 
overnight in LB broth (50 µg/mL ampicillin, 0.5% glucose) at 37°C.  Plasmid purification of the 
overnight cultures was performed using the Qiagen DNA Extraction Kit according to the 
manufacturer's instructions.  Extracted DNA was subjected to PCR amplification using the 
previously mentioned conditions, screened on a 1% agarose gel to assess purity, and was sent for 
sequencing at GENEWIZ to determine if the amplified DNA fragment's orientation within the 
plasmid was correct. 
 
Gene Expression and Purification 
 The Del 60, Del 90, and Del 110 recombinant BL21 E. coli mutants were each grown in 
LB media (6L, 100 µg/mL ampicillin, 100 µg/mL chloramphenicol) at 37°C for 2.5 hours.  
Protein expression was induced with IPTG (1 mM/mL) and the cultures were allowed to incubate 
for an additional 2 hours at 37°C.  The bacteria were harvested from 6 L of media via low speed 
centrifugation and the bacterial pellet was resuspended in 50 mL equilibration buffer (60 mM 
sodium phosphate, 300 mM NaCl, 10 mM imidazole; pH 7.4).  The resuspended homogenate 
was centrifuged (10000 RPM, 30 min, 4°C) and the resulting supernatant was applied to Thermo 
Scientific HisPur Cobalt Spin Columns (3 mL) (Pierce, Rockford, IL).  Recombinant proteins 
were eluted with 6 mL of elution buffer per column (50 mM sodium phosphate, 300 mM NaCl, 
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150 mM imidazole; pH 7.4).  Protein concentration of each fraction was determined via 
spectrophotometry and fractions containing the highest concentration were combined and 
concentrated using Centriprep-10 centrifugal filter units (Amicon, Beverly, MA). 
 
Protein Analysis 
 Polyacrylamide gel electrophoresis was performed with the Laemelli SDS PAGE system.  
The proteins were diluted 1:4 with sample buffer (97 mM Tris-HCL pH 6.8, 15.5% w/v glycerol, 
3.1% SDS, 40 mM BME, 0.0025% bromophenol blue.  The samples were then loaded on a 
polyacrylamide separating gel (37.5%T, 1%C) using the Bio-Rad mini gel system and run for 1-
1.5 hrs at 150V with running buffer (25 mM Tris, 320 mM glycine 1% SDS, pH 6.8). 
Polyacrylamide gel electrophoresis was also performed with a native β-alanine gel system.  The 
samples were loaded on a polyacrylamide separating gel (30%T, 2.7%C) using the Bio-Rad mini 
gel system and run for 1-1.5 hrs at 150V with running buffer (80 mM β-alanine, 40 mM Acetic 
acid, pH 4.4).  
 
 
 
 
 
 
 
 
 
	   12	  
 
Results and Discussion 
 
 The successfully created deletion constructs are depicted in the amino acid sequence, 
with each highlighted region representing the deleted amino acids corresponding to a particular 
mutant (Figure 2).  The pink region corresponds to ∆141-171, mutant 16; yellow region 
corresponds to ∆110-171, mutant 110; blue region corresponds to ∆90-171, mutant 90; Green 
region corresponds to ∆60-171, mutant 60.  Domains I, II, III, IV, and V are underlined and in 
bold font. They are depicted in consecutive order from the N-terminus.  
 
Figure 2. 
KWATIVGKRA KGPASGPTTN WGIPNSAICS SGFSGTTTPT VPSVSGNKPV  
TTIQQLSLTT SGSAAVDLCT IQAVSLLPGE PPQKIPTGVY GPLPEGTVGL  
ILGRSSLNLK GVQIHTSVVD SDYKGEIQLV ISSSIPWSAS PRDRIAQLLL LPYIKGGNSE 
IKRIGGLVST D 
 
 
 The consensus HERV-K sequence was used for PCR amplification of the target regions 
to produce the Del 60, Del 90, and Del 110 deletion constructs (Figure 3A).  The 5' and 3' 
primers utilized in the PCR reactions are depicted in Figure 3B.  
 
Figure 3A 
ggccccacaacaaactggggcattcccaattcagccctttgttcctcaagggttttcagggacaacaacccccactgtcccaagtacctcag
ggaataagccagttaccacaatacaacaattgtcccccaccacaagcaacagtgcagcagtagatttatgtactatacaagcagtctgtctgc
ttccaggggaacccccacaaaaaatccccacaggggtatacggcccgctgcctgaggggactgtaggacttgtcttgggaagatcaagtc
taaatccaaagggagttcaaattcatactggtgtggttgattcagactataaaggtgaaattcaattgattattagctcttcaattccttgcagtgc
cagtccaggagacaggatttctcaattattactcttgacttacattaaggttggaaatagtgagataaaaagaacaggaggatttggaagcac
ggatctgacaggaaaggctgcatattgggcaagt 
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Figure 3B. 
HERV-K 5’ Primer 
5’- F: GGATCCAAATGGGCAACCATTGTCGGGAAAC 
HERV-K 3’ Primers 
1. ∆110: 5’- GAATTCTCACCTTTTAGATTTAGACTTGATCTT-3’ 
2. RC16∆90: 5’- GAATTCTCATATACCCCTGTAGGGATTTTT-3’   
3. RC16∆60: 5’- GAATTCTCAGTGGTGAGGGACAATTGTTGTATT-3’ 
 
 
 Amplified deletion constructs were cloned into the pTrcHis Topo TA cloning vector 
(Figure 4).  Presence of the 6 histidine residues adjacent to the multiple cloning site allowed for 
expressed recombinant proteins to have a built in histidine tag that permitted purification via 
affinity chromatography with the HisPur Cobalt Affinity Columns. 
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Figure 4. 
 
 
 Recombinant protein purity and size was determined via electrophoresis with the 
Laemmli SDS PAGE system.  The SDS gels revealed a single band at the appropriate molecular 
weight as determined by sequence analysis (data not shown). 
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Future Studies 
 
 Luciferase assays using HEK-293 stable cell lines expressing TLR2 and an NF-κB 
reporter gene have been performed.  Analysis of the data is underway and a lack of NF-kB 
activation should indicate the ability of mutant recombinant proteins to activate TLR2.  Once this 
process is completed, the specific amino acid region responsible for binding TLR2 and 
subsequently activating NF-kB will be determined.  Furthermore, collaboration with 
crystallographer, Dr. Ganesaratriam Balendra, University of Akron, will allow for the 
determination of the crystal structure of the mutant protein interacting with TLR2.  With this 
additional data, our research group will pursue fine point mutational development to identify the 
specific amino acid that is binding to TLR2.  Identification of this residue will enable our 
research group to pursue development of a vaccine to generate antibodies that specifically target 
this region and thereby inhibit TLR2 activation.  It is our belief that successful completion of our 
studies, and future drug development based upon our findings, will lead to production of a novel 
alternative treatment option for psoriasis patients. 
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